Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas.

Suparna Mazumder Valerie Swank Nina Dvorina Justin M Johnson Vincent K Tuohy

Published in: Clinical and experimental vaccine research (2022)

Our data indicate that the AMHR2-ED vaccine formulated with AddaVax may be used in human clinical trials and thereby serve as a novel and effective way to control human EOC.

Keyphrases

endothelial cells
clinical trial
induced pluripotent stem cells
emergency department
pluripotent stem cells
drug delivery
randomized controlled trial
electronic health record
machine learning
big data
deep learning
artificial intelligence
open label
phase iii